Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 513-527 , September 2007

Stem-cell transplantation in chronic lympocytic leukaemia

  • John G. Gribben, MD, DSc (Professor of Experimental Cancer Medicine, Institute of Cancer)

      Affiliations

    • Corresponding Author InformationTel./Fax: +44 20 7882 6126.

References 

  1. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103(4):1202–1210
  2. Seiler T, Dohner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Seminars in Oncology. 2006;33(2):186–194
  3. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. The New England Journal of Medicine. 1987;316:1493–1498
  4. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology. 2003;21(21):3918–3927
  5. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology. 2002;118(2):385–400
  6. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232–1240
  7. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia–results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357–2366
  8. Sebban C, Lepage E, Vernant JP, et al. Allogeneic marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 1994;12(12):2580–2587
  9. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine. 1996;335(2):91–97
  10. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine. 2000;343(26):1910–1916
  11. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847
  12. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854
  13. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The New England Journal of Medicine. 2003;348(18):1764–1775
  14. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine. 2004;351(9):893–901
  15. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet. 2004;363(9403):105–111
  16. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12–17
  17. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885–891
  18. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology. 2005;23(18):4079–4088
  19. Hallek M. Chronic Lymphocytic Leukemia (CLL): First-Line Treatment. Hematology/The Education Program of the American Society of Hematology. 2005;285–291
  20. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. 2004;103(7):2850–2858
  21. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993;82(4):1366–1376
  22. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood. 2005;106:4389–4396
  23. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic marrow transplantation for chronic lymphocytic leukemia: preliminary results. Journal of Clinical Oncology. 1994;12(4):748–758
  24. Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukemia: a chance for cure?. British Journal of Cancer. 1998;77(12):2291–2297
  25. Pavletic ZS, Bierman PJ, Vose JM, et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Annals of Oncology. 1998;9(9):1023–1026
  26. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005;105(1):397–404
  27. Jantunen E, Itala M, Siitonen T, et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukemia: the Finnish experience. Bone Marrow Transplantation. 2006;37(12):1093–1098
  28. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia. 1998;12(11):1699–1707
  29. Itala M, Pelliniemi TT, Rajamaki A, et al. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplantation. 1997;19(7):647–651
  30. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP). British Journal of Haematology. 2000;108(3):595–601
  31. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98(1):29–35
  32. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after marrow transplantation. Blood. 1996;88(6):2228–2235
  33. Schey S, Ahsan G, Jones R. Dose intensification and molecular responses in patients with chronic lymphocytic leukemia: a phase II single centre study. Bone Marrow Transplantation. 1999;24(9):989–993
  34. Schultze JL, Donovan JW, Gribben JG. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. Journal of Molecular Medicine. 1999;77(2):259–265
  35. Zenz T, Ritgen M, Dreger P, et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;108(6):2127–2130
  36. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology. 2006;24(15):2337–2342
  37. Jantunen E, Itala M, Siitonen T, et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1482 patients transplanted in 1990–2003. European Journal of Haematology. 2006;77(2):114–119
  38. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2003;101(5):2049–2053
  39. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for blood and marrow transplantation and the International marrow transplant registry. Annals of Internal Medicine. 1996;124:311–315
  40. Khouri I, Champlin R. Allogenic marrow transplantation in chronic lymphocytic leukemia. Annals of Internal Medicine. 1996;125(9):780–787
  41. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplantation. 2000;25(7):717–722
  42. Doney KC, Chauncey T, Appelbaum FR. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplantation. 2002;29(10):817–823
  43. Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. British Journal of Haematology. 1997;97(2):466–473
  44. Toze CL, Galal A, Barnett MJ, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplantation. 2005;36(9):825–830
  45. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology. 2005;23(15):3433–3438
  46. Horowitz M, Montserrat E, Sobocinski K, et al. Haemopoietic stem cell transplantation for chronic lymphocytic leukemia. Blood. 2000;96(supplement 1):522a
  47. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. Journal of Clinical Oncology. 1998;16:2817–2824
  48. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology. 2003;21(14):2747–2753
  49. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003;17(5):841–848
  50. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 2005;23:3819–3829
  51. Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology/The Education Program of the American Society of Hematology. 2006;390–397
  52. Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biology of Blood and Marrow Transplantation. 2006;12(10):1056–1064
  53. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98(13):3595–3599
  54. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107(4):1724–1730
  55. Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19(6):1029–1033
  56. Caballero D, Garcia-Marco JA, Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clinical Cancer Research. 2005;11(21):7757–7763
  57. Khouri IF, Saliba RM, Keating MJ. ZAP-70 status may not predict outcome after non-myeloablative allogeneic transplantation (NMT) in patients with chronic lymphocytic leukemia (CLL) who failed conventional chemotherapy. Blood. 2005;106(supplement 1):577a

PII: S1521-6926(07)00040-0

doi: 10.1016/j.beha.2007.03.003

Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 513-527 , September 2007

Article Tools

* Image Usage & Resolution